LazyJ
VIP
- Liittynyt
- 6.7.2011
- Viestejä
- 1 195
Lancetin uutta tutkimusta kuinka se taudin sairastamalla saatu luomuimmuniteetti kestääkin sitten yllättäen yli 10kk vahvana. Omikronin suhteen nopeampi, mutta tauti onkin moninkertaisesti lievempi myös.
Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis
Ainoa yllätys on, että tutkimuksen on rahoittanut Billy boy.
Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis
Protection from past infection against re-infection from pre-omicron variants was very high and remained high even after 40 weeks. Protection was substantially lower for the omicron BA.1 variant and declined more rapidly over time than protection against previous variants. Protection from severe disease was high for all variants. The immunity conferred by past infection should be weighed alongside protection from vaccination when assessing future disease burden from COVID-19, providing guidance on when individuals should be vaccinated, and designing policies that mandate vaccination for workers or restrict access, on the basis of immune status, to settings where the risk of transmission is high, such as travel and high-occupancy indoor settings.
This study provides a comprehensive review of studies that have estimated the protection from past COVID-19 infection by variant and time since infection. The result shows high levels of protection against re-infection for ancestral, alpha, and delta variants for all major outcomes. Our analysis found significantly reduced protection against re-infection from the omicron BA.1 variant but that levels of protection against severe disease remained high. Although protection from re-infection from all variants wanes over time, our analysis of the available data suggests that the level of protection afforded by previous infection is at least as high, if not higher than that provided by two-dose vaccination using high-quality mRNA vaccines (Moderna and Pfizer-BioNTech), as documented by Nassereldine and colleagues, in our companion study. To our knowledge, this is the first review to comprehensively assess natural immunity protection against COVID-19 re-infection by variant (primary infection and re-infection) and to evaluate waning immunity with time since primary infection.
Ainoa yllätys on, että tutkimuksen on rahoittanut Billy boy.